Nonsteroidal anti-inflammatory drugs possess antiproliferative activities that can affect cancer cells. The aim of this study was to examine the antiproliferative effects of ibuprofen on the MKN-45 cell line. Cells were treated with ibuprofen for 24, 48 or 72 h, and cell proliferation was evaluated by cell counting and [ 3 H]-thymidine incorporation. Using microarray technology, we studied changes in the gene expression profiles over time after ibuprofen treatment. Ibuprofen induced a dose-and time-dependent reduction in cell number without altering cell viability. Genes involved in the 'biological oxidation' and 'G 1 /S checkpoint' pathways were the most significantly represented at 24 h, whereas genes involved in the 'cell cycle' and 'DNA replication' pathways were represented at 48 and 72 h. Genes associated with the 'apoptosis' pathway were also significantly represented at 72 h. Modulation of the expression of p53 and p53-induced genes (CDKN1A/ p21 and GADD45), which are involved in the G 1 /S transition, suggested an effect of ibuprofen on cell-cycle progression. Using flow cytometry, we observed an early block in the G 1 phase of the cell cycle after ibuprofen treatment. In addition, P450 family transcripts were upregulated and intracellular reactive oxygen species (ROS) was increased following 12 h of ibuprofen treatment. Ibuprofen induced ROS, which resulted in cellular alterations that promoted a p53-dependent G 1 blockade. These findings suggest that ibuprofen exerts its antiproliferative actions through cell-cycle control and the induction of apoptosis. Both of these mechanisms appear to be independent of ibuprofen's anti-inflammatory effects.
Introduction
Nonsteroidal anti-inflammatory drugs (NSAIDs) are primarily used as analgesics for the relief of pain and to control inflammation. 1 NSAIDs inhibit cyclooxygenase (COX) activity and the synthesis of prostaglandins, which are mediators of inflammation. Numerous epidemiological, clinical and laboratory studies have also suggested that NSAIDs inhibit the promotion and proliferation of some tumors. [2] [3] [4] [5] [6] [7] [8] [9] However, the antiproliferative activity of NSAIDs requires concentrations that are 100-to 1000-fold more than the concentrations necessary to inhibit COX activity.
COX-2-independent apoptosis induction has been described in HT29 colon cancer cells. Apoptosis was induced in these cells by the inhibition of 3-phosphoinositidedependent kinase 1 (PDK1). 11 One of the effects of NSAIDs is a reduction in hypoxia-inducible factor (HIF) protein levels. HIF-1a and HIF-2a are considered to be potential targets for antineoplastic therapy because they regulate the expression of genes that contribute to tumor cell survival, aggressiveness and angiogenesis. NSAIDs inhibited HIFs and HIF-regulated gene expression in prostate cancer DU-145 cells that did not express COX-2 protein. 12 Apoptosis and a cell-cycle blockade were observed in HCT-15 colon carcinoma cells that expressed only COX-1 (and not COX-2) and produced very low levels of prostaglandin E 2 . 13 These studies suggest the existence of other targets or COX-independent mechanisms that are responsible for the antiproliferative effects of NSAIDs. Microarray studies have shown alterations in genes that regulate the cell cycle, cell proliferation, cell death and cell-cell communication following treatment with nonspecific and/or COX-2-specific NSAIDs.
14 NSAIDs also alter cell-cycle progression, inhibit cyclins, modulate the Bcl-2 family of proteins and induce apoptosis. In addition, NSAIDs inhibit angiogenesis, which is an important process necessary for tumor growth and survival. 11, 12, [15] [16] [17] [18] [19] [20] Thus NSAIDs affect cellular targets in both COX-2-dependent and -independent manners.
The aim of this study was to investigate the antiproliferative effects of ibuprofen, a commonly used NSAID, on the MKN-45 human gastric adenocarcinoma cell line. To study the molecular mechanisms by which ibuprofen may exert its antiproliferative activity on gastric cancer cells, we performed gene expression analysis by using microarray technology.
Materials and methods

MKN-45 human gastric adenocarcinoma cells were obtained from German Collection of Microorganisms and Cell
Cultures (DSMZ) (Braunschweig, Germany). This cell line was originally derived from a poorly differentiated medullary adenocarcinoma. The cells were characterized for the presence of cytokeratin proteins and were confirmed as being from a human origin by using the aspartate aminotransferase isoelectric focusing technique. All cells were negative for mycoplasma and virus. Cells were grown as monolayer cultures in RPMI 1640 supplemented with 20% fetal bovine serum and 2 mM glutamine. Cells were incubated at 37 1C in a humidified atmosphere of 95/5% air/ CO 2 and were subcultured twice per week. All tissue culture reagents were obtained from Lonza (Basel, Switzerland). Ibuprofen was purchased from MP Biomedicals (Illkirch, France). Ibuprofen was prepared fresh in dimethyl sulfoxide and sterilized before being adding to cells. Control cells were treated with equivalent amounts of dimethyl sulfoxide.
Experimental design
Approximately 3 Â 10 5 cells per well were seeded in six-well plates, with 3.0 ml of medium used per well. Exponentially growing cells were treated with different concentrations of ibuprofen (ranging from 400 to 800 mM) for 24, 48 or 72 h. Ibuprofen was added daily. Cell proliferation was monitored daily by enumerating viable cells using a hemocytometer. Viability was determined by using Trypan blue dye exclusion. A Nikon (Tokyo, Japan) inverted phase-contrast microscope with a Â 20 ph objective and a camera port was used to examine the cells and collect images.
Cell proliferation assays [
3 H]-thymidine incorporation was used to assess cell proliferation. For thymidine incorporation, cells in logarithmic growth phase were detached using 0.25% trypsin and seeded in culture media (with 20% fetal bovine serum) in 24-well plates (1 Â 10 4 cells per well). Cells were treated with 600 or 800 mM ibuprofen for 8, 16 or 24 h. At the end of the treatment, 2 mCi [ 3 H]-thymidine (GE Healthcare, Amersham, UK) was added with fresh medium, and the cells were incubated for 4 h at 37 1C. Cells were then washed with phosphate-buffered saline at 4 1C and solubilized before scintillation counting (TriCarb 2100TR; Packard, Palo Alto, CA, USA).
Clonogenic assay
Cells were treated with ibuprofen (ranging from 400 to 800 mM) for 24, 48 or 72 h, as described in the Experimental design section. After the indicated times, the cells were trypsinized and counted, and 50 cells were plated in triplicate in six-well plates for the clonogenic assay. Colonies were stained with crystal violet after 12 days, and colonies of 450 cells were counted.
RNA isolation
The RNeasy Plus Micro Kit (Qiagen, Hilden, Germany) was used to extract total RNA from MKN-45 cells treated with 400, 600 or 800 mM of ibuprofen for 24, 48 or 72 h. RNA was also isolated from control MKN-45 cells grown for 24, 48 or 72 h without ibuprofen. Contaminating genomic DNA was removed using gDNA Eliminator spin columns (Qiagen). The purity and integrity of the isolated RNA were determined using a spectrophotometer, denaturing agarose gel electrophoresis and an Agilent 2100 Bioanalyzer (Agilent, Santa Clara, CA, USA). The RNA integrity number values of the isolated RNA were nearly to 10.
Oligo Microarray analysis
Total RNA (500 ng) isolated from MKN-45 cells treated with ibuprofen was amplified and labeled with cyanine 5 (Cy5) for use in generating complementary RNA (cRNA) with a two-color Quick Amplification Labeling Kit (Agilent). RNA from control MKN-45 cells was labeled with cyanine 3 (Cy3) and used as a reference. The resulting labeled cRNA samples were combined and hybridized to the same microarray. Whole human genome oligo microarrays (44K, 60-mer oligo microarrays; Agilent) that contained 41 000 unique human genes and transcripts, all with public domain annotations, were used. The sensitive detection limit was 1 mRNA copy in 6.9 million transcripts. A total of 27 microarrays (n ¼ 9 per
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For each replication, 750 ng of Cy5-labeled, linearly amplified cRNA obtained from the treated cells and 750 ng of Cy3-labeled, linearly amplified cRNA obtained from the control cells were used for cohybridization experiments using a Gene Expression Hybridization Kit (Agilent). Briefly, samples were incubated in 2 Â fragmentation buffer at 60 1C for 30 min. The hybridization was carried out with 250 ml of hybridization buffer and the Arabidopsis control target at 65 1C for 17 h. One wash was performed for 1 min at room temperature (RT) with buffer 1 (Agilent), and one wash was performed with buffer 2 (Agilent) for 1 min at 37 1C. Both buffers contained 0.005% Triton X-102. The slides were then washed with acetonitrile at RT for 1 min and then with a stabilization and drying solution (Agilent) at RT for 30 s.
Hybridized slides were scanned using an Agilent scanner. The maximum intensity was set at 65 500 in both channels, although we scanned the arrays to ensure that less than 1% of the total number of spots had median intensities near the maximum. Images were analyzed using Feature Extraction 9.5 image analysis software (Agilent). Spots showing no signal or obvious defects were flagged using GeneSpring GX 10.0.2 software (Silicon Genetics, Santa Clara, CA, USA) and excluded from the analysis. The local background was subtracted from the remaining spots, and the ratio of net fluorescence from the Cy5-specific channel to the net fluorescence from the Cy3-specific channel was calculated for each spot; this ratio represented the mRNA expression in the treated cells relative to the reference cells. For each single DNA array, spots with an absolute expression level of less than 3 standard deviations (s.d.) above background (after the removal of local background) were flagged as absent, as any ratios below this detection level may not be reliable. A Lowess normalization was applied for each different array.
Statistical analysis of microarrays
To select genes that were differentially expressed between the treated and untreated cells, we performed a one-way analysis of variance followed by a Tukey's honestly significant differences pair-wise comparison. The BenjaminiHochberg false discovery rate was used to correct for multiple testing, and the asymptotic P-value computation was used to calculate P-values. Genes that satisfied the significant analysis criteria were used for the fold-change analysis. A fold-change cutoff of values greater than 2 was used.
Pathway analysis
Pathway analysis was carried out using GeneSpring GX 10.0.2 software, which supports the BioPAX pathways/ network exchange format (OWL). The Significant Pathways table shows the names of the pathways, the number of nodes and entities in the pathway, and the P-values. It also shows the number of entities that are similar to the pathway and the entity list. The P-values represent the probability of obtaining that particular pathway as a result by chance when these sets of entities are used.
Flow cytometry analysis of DNA content and bromodeoxyuridine incorporation For monoparametric cell-cycle analysis, we collected control and treated cells, washed in phosphate-buffered saline (PBS) and fixed with cold 70% ethanol for a minimum of 24 h at 4 1C. Then, 2 Â 10 6 cells were washed twice in PBS and incubated with 2 ml of 20 mg ml À1 propidium iodide (Sigma-Aldrich, St Louis, MO, USA) in PBS containing 0.002% Nonidet P40 (Roche Applied Science, Penzberg, Germany) and 12.5 mg ml À1 RNase A (Sigma-Aldrich) at RT for a minimum of 60 min. For each sample, at least 20 000 cells were analyzed for DNA content using a FACSCalibur flow cytometer (BD Biosciences, Erembodegem, Belgium). The DNA histogram was analyzed for cell-cycle progression using ModFit LT v3.0 software (Verity Software House, Topsham, ME, USA).
For 5-bromo-2-deoxyuridine (BrdU) incorporation, we treated exponentially growing cells with 20 mM BrdU (SigmaAldrich) for 15 min at 37 1C, rinsed twice with prewarmed medium and incubated at 37 1C with fresh medium containing ibuprofen. At different time intervals during treatment, both control and treated cells were fixed in 70% ice-cold ethanol and stored at 4 1C before staining.
Fixed cells were washed in PBS and incubated in 3 N HCl for 20 min at RT to denature the DNA. The acid solution was neutralized with 0.1 M Na 2 B 4 O 7 (pH 8.5), and the cell suspension was washed in PBS. Cells were then incubated for 60 min at RT with a fluorescein-isothiocyanate-conjugated mouse anti-BrdU monoclonal antibody (BD Biosciences) in PBS containing 0.5% Tween 20 (USB, Staufen, Germany) and 1% BSA (Sigma-Aldrich). After being washed, cells were resuspended in 2 ml of a solution containing 5 mg/ml propidium iodide in PBS and then stained overnight at 4 1C. Biparametric BrdU/DNA analysis was performed on at least 20 000 cells for each sample using the FACSCalibur system. Data were analyzed using CellQuest software (BD Biosciences).
Determination of reactive oxygen species
Reactive oxygen species (ROS) were detected using dihydroethidium (hydroethidine). Cytosolic dihydroethidium shows blue fluorescence. However, once this probe is oxidized to ethidium, it intercalates within DNA and stains the cell's nucleus a bright fluorescent red. Briefly, ibuprofen-treated cells and control cells were incubated with fresh medium containing 5 mM hydroethidine (Molecular Probes, Eugene, OR, USA) at 37 1C for 40 min. The cells were then collected by trypsinization and washed with cold PBS. The ROS content was determined using flow cytometry.
For the restoration of ibuprofen-induced ROS, we co-treated cells with 800 mM ibuprofen and 5 mM N-acetylcysteine (Sigma-Aldrich) for 16 or 24 h. Cells were then collected and analyzed for ROS content.
Antibody microarrays
The Panorama Antibody Microarray XPRESS Profiler kit (Sigma-Aldrich) was used. The antibody microarray is composed of 725 highly specific antibodies spotted in duplicate onto nitrocellulose-coated glass slides. The complete list of arrayed antibodies can be found at the Sigma-Aldrich website (http://www.sigmaaldrich.com/). Cells at B80% confluence were collected for protein extraction, washed twice in cold PBS and lysed with Buffer A (an Antibody Microarray kit component) according to the manufacturer's instructions. The protein concentration was determined using the Bradford Assay (Bio-Rad, Philadelphia, PA, USA). Extracts with a protein concentration equal to 1.0 mg ml À1 were fluorescently labeled. A dual fluorescent-labeling assay analogous to that used in DNA microarray experiments was used. For the purpose of this study, three biological replicates were analyzed. In each replicate, control MKN-45 cells were labeled with Cy3, and MKN-45 cells treated with 600 mM ibuprofen for 48 h were labeled with Cy5. Two dye-swap labeling experiments were also conducted. Only samples with a dye-to-protein molar ratio greater than two were analyzed using the antibody microarray, as recommended in the protocol. The hybridized antibody microarray slides were scanned using a VersArray Confocal Scanner (Bio-Rad) with 532 and 635 nm lasers. Primary analysis was performed using the VersArray ChipReader (version 3.0) software (Bio-Rad). Image analysis was performed using VersArray Analyzer (version 5.0) software (Bio-Rad). Normalized data are presented as the log2 of the mean ratio of Cy5 to Cy3 signals.
Real-time PCR assay
Total RNA, isolated from cells as described above, was used for cDNA synthesis. Real-time quantitative RT-PCR analyses for E2F transcription factor 1 (E2F1), growth arrest and DNA-damage-inducible-g (GADD45G), ribonucleotide reductase M2 polypeptide (RRM2) and cyclin-dependent kinase 1 (CDK1 or CDC2) were performed with an ABI PRISM 7000 Sequence Detection System instrument and software (Applied Biosystems, Foster City, CA, USA) using the Power SYBR Green PCR Master Mix (Applied Biosystems) with the thermocycler conditions recommended by the manufacturer. All reactions were performed in a total volume of 25 ml containing 50 ng of cDNA and 2.5 ml of the 10 Â QuantiTect Primer (Qiagen). Reactions were carried out in triplicate on three independent sets of RNA. The QuantiTect Primers have been bioinformatically validated to detect RNA only, provided that no pseudogenes with high cDNA similarity exist or the transcript is not derived from a single-exon gene. Negative controls (no RNA added) were processed under the same conditions as experimental samples. Human glyceraldehyde 3-phosphate dehydrogenase (GAPDH) was used as an endogenous control to normalize target gene expression (DC t ) and to correct for experimental variation. The relative gene expression was calculated using the method described by Livak and Schmittgen 21 and is expressed as the fold-change compared with the control.
Statistical analysis
All data are shown as the mean ± s.d. A Student's t-test was used to determine the statistical significance of the observed differences.
Results
Effect of ibuprofen treatment on gastric cancer cell proliferation
We treated the MKN-45 human gastric tumor cell line with ibuprofen at a range of concentrations from 400 to 800 mM for 24, 48 and 72 h, with cell proliferation monitored daily. The results showed that ibuprofen significantly inhibited the proliferation of MKN-45 cells in a time-and concentration-dependent manner (Po0.005 for the 400-600 mM range of concentrations at 24, 48 and 72 h; Figure 1 ). The Figure 3b . The difference in the number of cells per plate was due to the inhibitory effect of ibuprofen on the proliferation rate. Any morphological differences observed were not due to contact inhibition, because this did not occur in the control condition.
Clonogenic survival of ibuprofen-treated MKN-45 cells
The plating efficiency of dimethyl sulfoxide control cells was 0.98 ± 0.02, 0.74 ± 0.01, 0.53 ± 0.01 for 24, 48 and 72 h, respectively. The surviving fractions of cells treated with 400, 600 or 800 mM ibuprofen at 24 h were 1.23±0.01, 1.26 ± 0.06 and 1.17 ± 0.03, respectively, compared with the control. The surviving fractions of cells treated with 400, 600 or 800 mM of ibuprofen at 48 h were 0.94±0.01, 1.02 ± 0.02 and 1.06 ± 0.006, respectively, compared with the control. The surviving fractions of cells treated with 400, 600 or 800 mM ibuprofen at 72 h were 0.98±0.01, 1.11±0.01 and 1.15±0.02, respectively, compared with the control. Exposure to ibuprofen (400-800 mM range of concentrations) for 24, 48 and 72 h was not cytotoxic for the MKN-45 cells.
Microarray analysis of ibuprofen-treated MKN-45 cells
Of the 41 000 unique genes represented in the Agilent human whole-genome microarrays, the genes that were differentially expressed with a high level of confidence (more than two fold change; Po0.01) are reported in Figure 4 . An analysis of the differentially expressed genes showed that the number of genes increased when the (Figure 4a) . However, the fact that all three ibuprofen concentrations tested produced similar increases in gene expression at 72 h indicates a plateau effect. Nevertheless, data from the 48 h time point suggest that there is still some degree of a dose effect (that is, cells treated with 800 mM ibuprofen express twice as many genes as the cells treated with 400 mM ibuprofen). To fully verify the plateau hypothesis, it may be necessary to examine later time points, such as 96 or 120 h. When the analysis was performed on the basis of ibuprofen concentration, the number of differentially expressed genes did not show an increase (Figure 4b ), especially at the 24 and 72 h time points.
Venn diagrams in Figures 4c-e illustrate the comparison of differentially expressed genes in relation to the time of exposure and to the range of ibuprofen concentrations (Figures 4f-h) . Interestingly, the middle panel of Figure 4d shows that the number of genes (1889) for 800 mM ibuprofen-treated cells actually peaks at 48 h and subsequently decreases at 72 h. Thus, this 48-72 h post-treatment period is a critical time window in the regulation of genes at this ibuprofen dose.
Pathway analysis of differentially expressed genes in ibuprofen-treated MKN-45 cells
The functional significance of the differentially expressed genes that were altered by ibuprofen treatment was evaluated using GeneSpring GX software (Agilent) with BioPAX pathways. Genes with a minimum two fold change were selected for network generation and pathway analysis. We analyzed the pathways of differentially expressed genes in relation to the time of exposure. Only pathways with a Po0.01 were evaluated. Tables 1, 2 and 3 show the biological networks most affected by ibuprofen treatment No morphological changes were observed in nontreated control cells. The difference in the number of cells per plate was due to the inhibitory effect of ibuprofen on the proliferation rate. Morphological differences were not due to the presence of contact inhibition, because this did not occur in the control condition. Figure 4 Differentially expressed genes overview. Of the 41 000 unique genes represented in the Agilent human whole-genome microarrays, the genes that were differentially expressed with a high level of confidence (42-fold change; Po0.01) are reported. The analysis of differentially expressed genes showed that the number of genes increased when the analysis was performed on the basis of the treatment time, indicating that gene expression was time dependent under the test conditions (a). When the analysis was performed on the basis of ibuprofen concentration, the number of differentially expressed genes did not show an additional increase (b), especially at 24 and 72 h. Venn diagrams show a comparison of the differentially expressed genes in relation to the time of exposure (c-e) and to the range of concentrations (f-h).
after 24, 48 and 72 h, respectively. Treatment for 24 h (400-800 mM range) (Tables 1 and 4) affected the expression of genes belonging to the 'biological oxidations' group and, in particular, genes involved in the biotransformation of xenobiotics. Genes belonging to the cytochrome P450 (CYP) family were also significantly affected. Some CYP family genes were upregulated at all ibuprofen concentrations, whereas others showed changes in response to only a single concentration of ibuprofen, as shown in the Table 4 . The number of differentially expressed CYP family genes increased with increasing ibuprofen concentrations. Other differentially expressed genes belonged to cell-cycle pathways. The 'cell cycle, mitotic,' 'G 1 /S transition' and 'cell cycle checkpoint' groups of genes were affected. In particular, the 'G 1 /S DNA damage checkpoints' and 'p53-dependent G 1 /S DNA damage checkpoint' groups were the most significantly affected pathways. We observed a downregulation of cyclin D1 (CCND1) and cyclin dependent kinase 6 (CDK6) transcripts, as well as a decrease in cyclin E1 (CCNE1) and cell division cycle 25 homologue A (CDC25A) transcripts, which are involved in the G 1 /S transition. The genes belonging to the 'cell cycle checkpoint' group, including CCNE1, CDC25A, cell division cycle homologue C (CDC25C), cyclin A2 (CCNA2) and CDC2, were all downregulated. We observed an upregulation of TP53 transcripts and TP53 gene targets at 24 h, such as growth arrest and DNA-damage-inducible-b (GADD45B), growth arrest and DNA-damage-inducible-g (GADD45G), cyclindependent kinase inhibitor 1A (p21, Cip1) (CDKN1A) and cyclin-dependent kinase inhibitor 1C (p57, Kip2) (CDKN1C). In addition, an upregulation of tumor protein p53-inducible nuclear protein 1 (TP53INP1) and tumor protein p53-inducible protein 11 (PIG11) (TP53I11) transcripts was observed. Transcripts of Mdm2 p53-binding protein homologue (mouse) (MDM2) were also upregulated. When cells were treated for 48 h, the affected genes belonged to the 'cell cycle, mitotic,' 'G 1 /S transition,' 'DNA replication' and 'E2F-mediated regulation of DNA replication' pathways (Tables 2 and 4 ). TP53 was not differentially expressed, but TP53INP1 and tumor protein p53-inducible protein 3 (TP53I3) transcripts were upregulated. GADD45 was upregulated at 24 h and remained upregulated. Transcripts of MDM2, cyclin G2 (CCNG2) and tumor protein p63, commonly known as TP63 (TP73 L), were all upregulated at 48 h. However, the transcription factor E2F1 was downregulated at 48 h. Chromatin licensing and DNA replication factor 1 (CDT1), proliferating cell nuclear antigen (PCNA), RRM2, dihydrofolate reductase (DHFR), thymidylate synthetase (TYMS), polymerase (DNA-directed)-a 1 catalytic subunit (POLA1), polymerase (DNA-directed)-a 2 (70 kDa subunit) (POLA2), thymidine kinase 1 soluble (TK1), origin recognition complex subunit 1-like (yeast) (ORC1L) and origin recognition complex subunit 6-like (yeast) (ORC6L) were downregulated. In addition, minichromosome maintenance complex 2 (MCM2), 3 (MCM3), 5 (MCM5), 6 (MCM6) and 7 (MCM7) were also downregulated. DNA ligase I (LIG1), CDC45 cell division cycle 45-like (Saccharomyces cerevisiae) (CDC45L), CCNE1, CCNA2, CDC2, CDC25C and cyclin B1 (CCNB1) were all downregulated. The RRM2, TYMS, TK1 and DHFR genes are involved in the biosynthesis of purines and pyrimidines. At 48 h, we also observed that cytochrome c (CYCS) transcripts were upregulated. This suggests that an apoptotic program had been triggered due to the difficulty in repairing DNA damage.
When the cells were treated for 72 h (Tables 3 and 4) , the affected genes belonged to the 'cell cycle, mitotic,' 'E2F-mediated regulation of DNA replication,' 'G 1 /S transition,' 'DNA replication' and 'apoptosis' pathways. CDC25A, B and C and CDC2 were downregulated, as were CCNE1, CCNB1, cyclin B2 (CCNB2) and CCNA2 transcripts. TP53 and TP53I3 were upregulated, but TP53I11 was downregulated. MDM2, CCNG2 and TP73L transcripts were all upregulated. GADD45B and GADD45G were previously upregulated and remained at this state. In addition, growth arrest and DNA-damage-inducible-a (GADD45A) was upregulated. The transcription factor E2F1 was downregulated, as were RRM2, TYMS, DHFR, polymerase (DNA-directed)-d 1 (POLD1), polymerase (DNA-directed)-d 2 (POLD2) and polymerase (DNA-directed)-d 3 (POLD3). ORC1L, ORC6L, MCM2, MCM3, MCM4, MCM5, MCM7 and CDT1 transcripts were all downregulated. After 72 h of treatment, we observed a marked modulation of apoptosis-related transcripts. Initiator caspases, such as caspase-8 (CASP8), -9 (CASP9) and -10 (CASP10), as well as effector caspases such as caspase-3 (CASP3) and -7 (CASP7), were all upregulated. DNA fragmentation factor, 45 kDa, a-subunit (DFF45) and DNA fragmentation factor, 40 kDa, b-polypeptide (DFF40) transcripts were also upregulated. (Figure 6b ). Cells were also treated for 4 and 8 h with 800 mM ibuprofen. The cytofluorimetric analysis performed after 4 h of treatment showed that 53% of cells were in G 1 , 35% were in S and 12% were in G 2 /M phases (G 1 and G 2 /M Po0.001; S, Po0.01). After 8 h of treatment with 800 mM ibuprofen, 64% of the cells were in G 1 , 22% were in S and 14% were in G 2 /M phases (G 1 and G 2 / M Po0.001; S, Po0.01; data not shown). These results suggest that after 8 h of treatment, a small percentage of cells were blocked in G 1 . Thus, the block of cells in G 1 is an early event.
Effects of ibuprofen treatment on the cell cycle
BrdU cell-cycle kinetic studies of MKN-45 cells treated with 800 mM ibuprofen for 4, 16, 24 and 48 h showed that after 4 h of treatment ibuprofen did not substantially modify the cell-cycle distribution compared with the control cells, although the S-phase cells appeared to be delayed. At 16 h after treatment, we observed a decrease in the number of cells labeled by BrdU in the S phase and an accumulation of cells in the G 0 /G 1 phase. After 16, 24 and 48 h, we observed an accumulation of cells in the G 1 phase, whereas the control cells cycled with regularity (Figures 7a and b) .
These results suggest that the effects of ibuprofen on cell-cycle phases are time and concentration dependent.
Effect of ibuprofen on ROS generation
MKN-45 cells exposed to 800 mM ibuprofen for the indicated time periods were examined for changes in ROS generation using the specific fluorescence probe hydroethidine. In Figure 8 , typical fluorescence histograms show that exposure to 800 mM ibuprofen induces a shift of the hydroethidine fluorescence curve to the right. This finding indicates that ibuprofen exposure induced an increase of ROS generation. Figure 8 shows an increase in ROS levels 12 h after ibuprofen treatment. This increase in ROS levels continues with exposure time, reaches a peak value at 24 h and then decreases to basal levels at 48 h. These data confirm that the increase in ROS levels is not a simple cell death phenomenon. The changes at 24 h correlated with increases in the 'biological oxidation' pathway at 24 h (Table 1) . No significant increase in ROS levels was observed before 12 h. The levels of ROS in untreated control cells were unchanged over the entire time period analyzed. To reverse the ibuprofen-induced ROS generation, we co-treated cells for 16 and 24 h with 800 mM ibuprofen and the antioxidant agent N-acetyl-cysteine (5 mM).
The data in Figure 9 show that co-treatment with 5 mM of N-acetyl-cysteine at 16 and 24 h resulted in the complete inhibition of ibuprofen-induced ROS and produced a profile that was indistinguishable from that of the untreated controls.
Antibody microarrays analysis
The results of the protein expression profile analysis performed with antibody microarrays on 600 mM ibuprofentreated cells for 48 h are shown in Figure 10 . The data show that protein levels of p53, p21, MDM2, retinoblastoma, caspase-3, -6, -7, -8 and -9 are upregulated. E2F1, CDC25A and PCNA protein levels are downregulated. observed an inhibitory effect of ibuprofen on cell proliferation in vitro. This result is in agreement with previously reported data from similar experiments conducted in vitro using other tumor cell lines [22] [23] and in vivo on xenografts of MKN-45 cells. 24 Our study results showed that when ibuprofen was used at concentrations ranging between 400 and 800 mM, the cell proliferation rate was significantly reduced in a time-and concentration-dependent manner. Previous research showed that concentrations of ibuprofen comparable to those used in our study targeted a wide variety of cellular processes. 14, [25] [26] [27] Recent microarray studies on human prostate cancer cells have shown that high concentrations of ibuprofen did not modulated COX-2 target genes.
14 These studies suggest the existence of other targets or COX-independent mechanisms that are responsible for the antiproliferative effects of ibuprofen.
In this study, we showed that ibuprofen is involved in the cell cycle, by altering the distribution of cells among the different cell-cycle phases. Ibuprofen treatment caused MKN-45 cells to shift from the S and G 2 /M phases to the G 0 /G 1 phase of the cell cycle, resulting in a significant block of cells at the G 1 phase. These results are in agreement with previous studies using different cell lines. 14, [18] [19] [20] The cell-cycle changes caused by ibuprofen correlated with alterations in cell-cycle regulatory genes. Our microarray data revealed that ibuprofen treatment for 24 h affected Ibuprofen-mediated gene expression in MKN-45 cells P Bonelli et al genes belonging to the 'biological oxidations' and 'cellcycle' pathways. Many P450 gene family transcripts were modulated at all ibuprofen concentrations, and others were modulated at high concentrations of ibuprofen. The upregulation of these transcripts correlated with the 'biological oxidations' pathway, which was the most significantly affected pathway at 24 h. The upregulation of this pathway correlated with the increases in intracellular ROS. At 24 h, most of the altered genes were G 1 /S transition genes, such as CDK6, CDKN1A and TP53. CDK6 is the key regulator of cell-cycle transition, 28 it has proto-oncogenic properties and its activity is carefully regulated at multiple levels. 29 CDKN1A is generally upregulated when it is necessary to block cells in the G 1 phase to permit the repair of damaged DNA before the entry of cells into the subsequent S phase. The expression of CDKN1A is tightly controlled by TP53, through which it mediates the p53-dependent cell-cycle G 1 phase arrest in response to different stress stimuli. 30 The microarray data related to TP53 signaling pathways are in agreement with a recent study. 14 The progression from G 1 phase to S phase requires the de novo expression of genes that encode proteins and enzymes involved in DNA replication. Regulation of S-phase genes is, therefore, an important component of G 1 progression.
The coordinated regulation of S-phase genes is principally controlled by the E2F family of transcription factors. 31 Treatment with ibuprofen for 48 h at all concentrations altered S-phase genes including E2F1 as well as the E2F1-regulated genes such as the ORCs, the MCMs, the nucleotide synthases and the DNA polymerases. Ibuprofen treatment also affected apoptotic genes, such as CYC, CASP3, CASP7 and BAG3. In addition, we observed an increase of caspase proteins after 48 h. In multiple cell types, apoptosis induced by a variety of stimuli is preceded by an early induction of mitochondrial respiratory chain proteins, such as cytochrome c. The upregulation of cytochrome c results from the transcriptional activation of the respective gene. Overexpression of cytochrome c enhances caspase activation and promotes cell death in response to apoptotic stimulation. 32 These results suggest that an apoptotic program was triggered due to the difficulty in repairing the DNA damage that occurred. Treatment for 72 h showed a marked modulation of apoptosis-related transcripts, including caspases and DFFs.
In conclusion, this study shows that the early alteration of cell-cycle regulatory genes and the later induction of apoptosis are the major mechanisms that account for the antiproliferative effects of ibuprofen on the MKN-45 human gastric cancer cell line. Treatment with ibuprofen altered the cell-cycle phase distribution of MKN-45 cells by inhibiting the G 1 /S transition. This arrest in G 1 was due to a decrease in the expression of cyclins and cyclin-dependent kinases as well as an increase in the expression of the cell-cycle inhibitory protein CDKN1A/p21. The induction of p21 appeared to be transcriptionally upregulated and p53 dependent. p53 signaling was activated early (24 h) as a result of an intracellular modification, perhaps due to oxidative stress leading to an increase in ROS. p21 and GADD45 were induced by stress through a p53-dependent pathway. GADD45 binds and synergises with p21 to elicit growth arrest. In addition to its ability to inhibit proliferation and to stimulate DNA repair, GADD45 can also induce apoptosis. In addition, a modulation of E2F transcription factors was involved in the downregulation of the transcription of cyclins and proteins involved in DNA precursor synthesis and the DNA replication system. The downregulation of cyclins involved in the G 1 /S transition and the downregulation of transcripts encoding enzymes involved in DNA precursor synthesis and the DNA replication system inhibited the proliferation of cells by blocking them in G 1 phase. The late upregulation of caspase transcripts suggests that an apoptotic program that involves mitochondrial activation was triggered secondary to the repair of cell damage.
Despite the high doses of ibuprofen required to elicit these effects, the molecular mechanisms implicated in this study suggest that NSAIDs such as ibuprofen may be of benefit in the treatment of certain types of gastric tumor.
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